Display options
Cite
Steerenberg PA, De Jong WH, Geerse E, et al. Major histocompatibility complex class II antigen expression during potentiation of line-10 tumor immunity after intralesional administration of bacillus Calmette-Guérin. Cancer Immunol Immunother. 1990;32(2):95-104doi: 10.1007/BF01754205.
Steerenberg, P. A., De Jong, W. H., Geerse, E., Aleva, B. J., Besselink, C. M., Van Rens, B. T., Rutten, V. P., Poels, L. G., Scheper, R. J., & Den Otter, W. (1990). Major histocompatibility complex class II antigen expression during potentiation of line-10 tumor immunity after intralesional administration of bacillus Calmette-Guérin. Cancer immunology, immunotherapy : CII, 32(2), 95-104. https://doi.org/10.1007/BF01754205
Steerenberg, P A, et al. "Major histocompatibility complex class II antigen expression during potentiation of line-10 tumor immunity after intralesional administration of bacillus Calmette-Guérin." Cancer immunology, immunotherapy : CII vol. 32,2 (1990): 95-104. doi: https://doi.org/10.1007/BF01754205
Steerenberg PA, De Jong WH, Geerse E, Aleva BJ, Besselink CM, Van Rens BT, Rutten VP, Poels LG, Scheper RJ, Den Otter W. Major histocompatibility complex class II antigen expression during potentiation of line-10 tumor immunity after intralesional administration of bacillus Calmette-Guérin. Cancer Immunol Immunother. 1990;32(2):95-104. doi: 10.1007/BF01754205. PMID: 1963114.
Copy Download .nbib Format: NLM
Share it on

Cancer Immunol Immunother. 1990;32(2):95-104. doi: 10.1007/BF01754205.

Major histocompatibility complex class II antigen expression during potentiation of line-10 tumor immunity after intralesional administration of bacillus Calmette-Guérin.

Cancer immunology, immunotherapy : CII

P A Steerenberg, W H De Jong, E Geerse, B J Aleva, C M Besselink, B T Van Rens, V P Rutten, L G Poels, R J Scheper, W Den Otter

Affiliations

  1. Laboratory for Pathology, National Institute of Public Health and Environmental Protection, Bilthoven, The Netherlands.

PMID: 1963114 DOI: 10.1007/BF01754205

Abstract

Intralesional injection of BCG into an established line-10 hepatocellular carcinoma in the strain-2 guinea pig causes regression of the tumor and induction of line-10 immunity. We found that the animals were already protected for a second challenge with line-10 tumor cells 7 days after BCG treatment. We studied whether this early induction of immunity was correlated with the expression of MHC class II antigens on line-10 tumor cells and was correlated with an increased expression of MHC class II antigens on leukocytes in the primary tumor and in the regional lymph node (Ln. axillaris accessorius). The MHC class II antigens and the leukocyte subpopulations were measured with monoclonal antibodies and flow cytofluorometry. In the draining lymph node the number of nucleated cells increased about 10-fold during the first 5 days after intralesional injection of BCG. At this time the MHC class II antigen expression of these cells was increased from 21%-32% in the naive controls to 39%-53% in animals with BCG-treated tumors. This implies that the number of MHC-class-II-positive cells increased about 20-fold in the draining lymph node. Surprisingly, the increase in percentage of MHC-class-II-antigen-positive cells was mainly due to an increase of IgM-positive B cells from 8%-11% to 22%-41% and an increase of IgG-positive B cells from 7%-27% to 25%-44%. In the tumor, BCG treatment induced a small increase of MHC-class-II-antigen-positive cells from 11%-12% to 15%-20%. Probably this increase came not from tumor cells but mainly from a BCG-induced infiltration of mononuclear cells, as an increase of T cells from 14% to 20%, an increase of macrophages from 8% to 18%, and an increase of B cells from 0 to 6% was observed. We conclude that the potentiation of anti-(line-10 tumor cell) immunity correlated with a 20-fold increase of MHC-class-II-antigen-positive cells in the lymph nodes and a small increase in the number of MHC-class-II-antigen-positive tumor-infiltrating cells.

Similar articles

References

  1. Transplantation. 1989 Mar;47(3):504-12 - PubMed
  2. Crit Rev Immunol. 1985;5(3):263-316 - PubMed
  3. Virchows Arch B Cell Pathol Incl Mol Pathol. 1990;59(4):185-94 - PubMed
  4. J Immunol. 1984 Jan;132(1):1-5 - PubMed
  5. J Exp Med. 1982 Dec 1;156(6):1755-66 - PubMed
  6. Eur J Immunol. 1987 May;17(5):723-6 - PubMed
  7. Hum Immunol. 1984 Dec;11(4):219-28 - PubMed
  8. J Exp Med. 1976 May 1;143(5):1067-81 - PubMed
  9. Am J Pathol. 1985 Sep;120(3):334-43 - PubMed
  10. J Leukoc Biol. 1987 Jan;41(1):47-54 - PubMed
  11. J Exp Med. 1975 May 1;141(5):1181-200 - PubMed
  12. J Immunol. 1989 Jul 15;143(2):762-9 - PubMed
  13. J Leukoc Biol. 1986 Nov;40(5):561-74 - PubMed
  14. Cancer Res. 1983 Jun;43(6):2637-43 - PubMed
  15. J Immunol. 1981 Jan;126(1):32-7 - PubMed
  16. J Leukoc Biol. 1985 Nov;38(5):635-47 - PubMed
  17. J Natl Cancer Inst. 1971 Apr;46(4):831-9 - PubMed
  18. Transplantation. 1983 Jan;35(1):56-61 - PubMed
  19. Virchows Arch B Cell Pathol Incl Mol Pathol. 1989;56(4):211-9 - PubMed
  20. Cancer Res. 1981 Sep;41(9 Pt 1):3499-506 - PubMed
  21. Immunology. 1985 Jul;55(3):519-30 - PubMed
  22. Cancer Res. 1985 Mar;45(3):1152-8 - PubMed
  23. Cancer Res. 1984 Aug;44(8):3208-14 - PubMed
  24. Blood. 1986 Feb;67(2):458-64 - PubMed
  25. J Immunol. 1980 Mar;124(3):1426-32 - PubMed
  26. J Exp Med. 1984 Jul 1;160(1):255-69 - PubMed
  27. J Leukoc Biol. 1986 Nov;40(5):499-509 - PubMed
  28. J Natl Cancer Inst. 1985 Sep;75(3):483-9 - PubMed
  29. Transplantation. 1973 Aug;16(2):126-33 - PubMed
  30. Hybridoma. 1985 Summer;4(2):115-24 - PubMed
  31. Clin Exp Immunol. 1986 Apr;64(1):20-7 - PubMed
  32. J Exp Med. 1983 Oct 1;158(4):1077-91 - PubMed
  33. Cancer. 1975 Oct;36(4):1298-304 - PubMed
  34. Prog Clin Biol Res. 1989;310:93-105 - PubMed
  35. Am J Clin Pathol. 1971 Mar;55(3):283-90 - PubMed
  36. Transplantation. 1974 Dec;18(6):544-8 - PubMed
  37. J Natl Cancer Inst. 1973 Dec;51(6):1897-908 - PubMed
  38. Immunology. 1984 Jan;51(1):93-102 - PubMed
  39. J Exp Med. 1980 Oct 1;152(4):1011-23 - PubMed
  40. Immunobiology. 1988 Apr;177(1):40-54 - PubMed
  41. Cancer Res. 1973 Apr;33(4):701-16 - PubMed
  42. J Immunol. 1989 May 1;142(9):3275-80 - PubMed
  43. Int Arch Allergy Appl Immunol. 1988;87(2):134-42 - PubMed
  44. Immunol Rev. 1983;76:29-57 - PubMed

Substances

MeSH terms

Publication Types

LinkOut - more resources